Newsletter Subject

Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Tue, Aug 29, 2023 10:53 PM

Email Preheader Text

Daily Headlines Tuesday, August 29, 2023 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGHT

[MEDPAGE TODAY]( Daily Headlines Tuesday, August 29, 2023 Today's Top Stories for {NAME} [ONCOLOGY/HEMATOLOGY]( [Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma]( [NEUROLOGY]( [Live Worm Removed From Woman's Brain]( [PSYCHIATRY]( [Certain SSRIs May Increase Arrhythmia Risk in Select Patients]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Navigating PNH Recognition, Diagnosis, and Treatment]( [NEUROLOGY]( [Parkinson's and Plant-Based Diets; AI and Dementia; Why Do Some People Develop ALS?]( [MEETING COVERAGE]( [No Aspirin After PCI? Extended P2Y12 Monotherapy? Trials Weigh In]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [SPECIAL REPORTS]( [Can COVID, Flu, and RSV Shots Be Given at the Same Time?]( CME SPOTLIGHT [Emerging Evidence in the Treatment of Chronic Lymphocytic Leukemia]( [OPINION]( [Do Advocacy Groups Always Put Patient Interests First?]( [ENDOCRINOLOGY]( [Insulin Calculator Cleared; Twice-Rejected Diabetes Drug; Ozempic for Alcohol Use?]( [ALLERGY & IMMUNOLOGY]( [Neighborhood Factors in Childhood May Influence Asthma Risk]( CME SPOTLIGHT [Novel Mechanisms and Therapeutic Targets in Relapsed/Refractory Multiple Myeloma]( [MEETING COVERAGE]( [Cancer Therapy's Lower-Limb Blood Clots Better Treated With Long Anticoagulation]( [MEETING COVERAGE]( [Novel Amyloid Drug Improves Mid-Term Outcomes in ATTR Cardiomyopathy]( [CARDIOLOGY]( [OCT Angioplasty Win; Congenital Defect Found in Bronny James; Gene Tx for Angina]( CME SPOTLIGHT [Applying the Latest Evidence for Anemia Management in Patients With Lower-Risk Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia]( [MEETING COVERAGE]( [Suprachoroidal Axitinib Shows Early Durability, Excellent Safety in Wet AMD]( [SPECIAL REPORTS]( [Company Selling Unproven Insulin Infusions in Legal Battle Over Money, Control]( [OPINION]( [How to (Legally) Diversify the Healthcare Workforce]( [CARDIOLOGY]( ['Big Win' for Anti-Obesity Medication in Heart Failure]( [WASHINGTON-WATCH]( [U.S. Unveils First 10 Drugs for Medicare Price Negotiations]( [MEETING COVERAGE]( [Compound in Beetroot Juice Fends Off Contrast-Induced AKI]( [ASCO READING ROOM]( [Manali Kamdar, MD, on Practical Considerations for Using CAR T-Cells for DLBCL]( [ASCO READING ROOM]( [Management of Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma]( # Weekly Survey [Should Patients Be Able to Hide Medical Records?]( Patients could ask their physicians [to hide parts of their medical record]( from other clinicians under a rule being considered by the federal health IT agency[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2023-08-29&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

31/05/2024

Sent On

31/05/2024

Sent On

31/05/2024

Sent On

31/05/2024

Sent On

30/05/2024

Sent On

30/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.